Massachusetts General Hospital: Myelodysplastic Syndromes trials

The registry lists 15 Myelodysplastic Syndromes studies with Massachusetts General Hospital as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 7Phase 2 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal HematopoiesisRecruitingNCT06691217Phase 2
• MBG453 in Lower Risk MDSTerminatedNCT04823624Phase 2Results posted
• Busulfan/Clofarabine + Allogeneic Stem Cell TransplantationCompletedNCT01643668Phase 2Results posted
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
• Inqovi Maintenance Therapy in Myeloid NeoplasmsActive, not recruitingNCT04980404Phase 1
• Acquired Pyruvate Kinase Deficiency In Clonal Myeloid NeoplasmsCompletedNCT04902833
• AZD6738 for Patients With Progressive MDS or CMMLActive, not recruitingNCT03770429Phase 1
• A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive TherapyActive, not recruitingNCT03310918Not applicable
• Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationCompletedNCT02312102Phase 1
• Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
• A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With MyelodysplasiaCompletedNCT00580242Phase 1
• Phase I Study of Sequential Cord Blood TransplantsCompletedNCT00299767Phase 1
• Study of Velcade and Thalidomide in Patients With MyelodysplasiaTerminatedNCT00271804Phase 1
• Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113828Phase 2
• Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113646Phase 2